pISSN 2234-3806eISSN 2234-3814
Table. 2.
Summary statistics of laboratory measurement results
| Drug | Participating laboratories (N) | Test sample | General without outlier removal | Robust statistics | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean ( |
Median ( |
|||||||||||
| TAC (ng/mL) | 10 | TAC-1 | 5.41 | 0.41 | 0.48 | 0.57 | 10.5 | 5.59 | 0.31 | 0.24 | 0.32 | 5.8 |
| TAC-2 | 8.93 | 0.39 | 0.57 | 0.63 | 7.1 | 8.84 | 0.24 | 0.19 | 0.25 | 2.8 | ||
| TAC-3 | 15.83 | 0.50 | 1.33 | 1.37 | 8.7 | 16.05 | 0.30 | 1.43 | 1.45 | 9.0 | ||
| SIR (ng/mL) | 9 | SIR-1 | 3.50 | 0.19 | 0.29 | 0.32 | 9.1 | 3.55 | 0.14 | 0.37 | 0.38 | 10.8 |
| SIR-2 | 5.83 | 0.36 | 0.88 | 0.92 | 15.7 | 5.55 | 0.27 | 0.67 | 0.69 | 12.5 | ||
| SIR-3 | 12.08 | 1.13 | 0.61 | 1.00 | 8.3 | 11.96 | 0.85 | 0.61 | 0.86 | 7.2 | ||
| EVE (ng/mL) | 9 | EVE-1 | 2.43 | 0.25 | 0.33 | 0.38 | 15.5 | 2.45 | 0.19 | 0.27 | 0.30 | 12.3 |
| EVE-2 | 3.53 | 0.39 | 0.36 | 0.46 | 12.9 | 3.55 | 0.27 | 0.36 | 0.40 | 11.4 | ||
| EVE-3 | 5.89 | 0.25 | 0.49 | 0.53 | 8.9 | 5.90 | 0.19 | 0.52 | 0.54 | 9.1 | ||
| CSA (ng/mL) | 8 | CSA-1 | 30.10 | 1.67 | 2.83 | 3.06 | 10.2 | 29.85 | 0.78 | 0.70 | 0.89 | 3.0 |
| CSA-2 | 63.78 | 2.32 | 3.77 | 4.12 | 6.5 | 63.45 | 1.15 | 2.37 | 2.51 | 4.0 | ||
| CSA-3 | 149.93 | 4.55 | 10.44 | 10.92 | 7.3 | 149.40 | 3.53 | 9.01 | 9.35 | 6.3 | ||
| MPA (mg/L) | 3 | MPA-1 | 0.76 | 0.06 | 0.06 | 0.07 | 9.3 | 0.77 | 0.04 | 0.07 | 0.07 | 9.6 |
| MPA-2 | 1.94 | 0.14 | 0.18 | 0.21 | 10.7 | 1.90 | 0.11 | 0.17 | 0.19 | 9.8 | ||
| MPA-3 | 5.16 | 0.08 | 0.12 | 0.14 | 2.6 | 5.10 | 0.06 | 0.04 | 0.06 | 1.1 | ||
Abbreviations: CSA, cyclosporine; EVE, everolimus; MPA, mycophenolic acid; TAC, tacrolimus; SIR, sirolimus.
Ann Lab Med 2021;41:268~276 https://doi.org/10.3343/alm.2021.41.3.268
© Ann Lab Med